Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis

Abstract

Background The COVID-19 pandemic has strained health system capacity worldwide due to a surge of hospital admissions, while mitigation measures have simultaneously reduced patients' access to health care, affecting the diagnosis and treatment of other diseases such as cancer. We estimated the impact of delayed diagnosis on cancer outcomes in Chile using a novel modelling approach to inform policies and planning to mitigate the forthcoming cancer-related health impacts of the pandemic in Chile. Methods We developed a microsimulation model of five cancers in Chile (breast, cervix, colorectal, prostate, and stomach) for which reliable data were available, which simulates cancer incidence and progression in a nationally representative virtual population, as well as stage-specific cancer detection and survival probabilities. We calibrated the model to empirical data on monthly detected cases, as well as stage at diagnosis and 5-year net survival. We accounted for the impact of COVID-19 on excess mortality and cancer detection by month during the pandemic, and projected diagnosed cancer cases and outcomes of stage at diagnosis and survival up to 2030. For comparison, we simulated a no COVID-19 scenario in which the impacts of COVID-19 on excess mortality and cancer detection were removed. Findings Our modelling showed a sharp decrease in the number of diagnosed cancer cases during the COVID-19 pandemic, with a large projected short-term increase in future diagnosed cases. Due to the projected backlog in diagnosis, we estimated that in 2021 there will be an extra 3198 cases (95% uncertainty interval [UI] 1356–5017) diagnosed among the five modelled cancers, an increase of nearly 14% compared with the no COVID-19 scenario, falling to a projected 10% increase in 2022 with 2674 extra cases (1318–4032) diagnosed. As a result of delayed diagnosis, we found a worse stage distribution for detected cancers in 2020–22, which is estimated to lead to 3542 excess cancer deaths (95% UI 2236–4816) in 2022–30, compared with the no COVID-19 scenario, among the five modelled cancers, most of which (3299 deaths, 2151–4431) are projected to occur before 2025. Interpretation In addition to a large projected surge in diagnosed cancer cases, we found that delays in diagnosis will result in worse cancer stage at presentation, leading to worse survival outcomes. These findings can help to inform surge capacity planning and highlight the importance of ensuring appropriate health system capacity levels to detect and care for the increased cancer cases in the coming years, while maintaining the timeliness and quality of cancer care. Potential delays in treatment and adverse impacts on quality of care, which were not considered in this model, are likely to contribute to even more excess deaths from cancer than projected. Funding Harvard TH Chan School of Public Health. Translations For the...

The impact of the COVID‐19 pandemic on cancer diagnosis based on pathology notifications: A comparison across the Nordic countries during 2020

“…In all countries, the consequences of the pandemic include risks of diagnostic delays that may lead to future increased rates of late‐stage cancer with poorer prognosis in cancer patient subgroups. 44 , 45 …”

“…Our findings may suggest that the severity of the pandemic has had larger effect on cancer detection than strict societal restrictions. In all countries, the consequences of the pandemic include risks of diagnostic delays that may lead to future increased rates of late‐stage cancer with poorer prognosis in cancer patient subgroups 44,45 …”

Impact of COVID-19 in Cervical and Breast Cancer Screening and Systemic Treatment in São Paulo, Brazil: An Interrupted Time Series Analysis

“…Some models expect substantial increases in breast, cervical, and colorectal cancer death. 8,47 Even a short two-week delay model was associated with an increase in cancer deaths in simulation models. 48 Our work has some limitations.…”

Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality

“…14 Ricciardiello et al constructed a procedural model for changes in CRC outcomes due to delays in screening colonoscopies and projected a more than 10% increase in CRC mortality with over 12-month delays in screening similar to our projections. 15 Furthermore, Ward et al projected over 3000 excess cancer deaths in Chile until 2025 due to stage migration during the pandemic 16 . In a pioneer report from the Netherlands, the new cancer diagnoses were decreased up to 30% in the first 2 months of the pandemic.…”